Jing Yawan, Zeng Hao, Cheng Ruixin, Tian Panwen, Li Yalun
Department of Respiratory and Critical Care Medicine, West China Hospital, Chengdu 610041, China.
West China School of Medicine, Sichuan University, Chengdu 610041, China.
Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):66-77. doi: 10.3779/j.issn.1009-3419.2023.102.03.
Immunotherapy has significantly improved clinical outcomes of non-small cell lung cancer (NSCLC), however, along with the popularization of immunotherapy, immune resistance has become an unavoidable problem. Immunotherapy can induce extensive cellular and molecular alterations in the tumor microenvironment. Considering the mechanisms of immune resistance are not yet fully understood and the efficacy of standard chemotherapy regimens is limited, more effective coping strategies based on resistance mechanisms are urgently needed. In this review, we intend to summarize the known mechanisms of immune resistance and feasible strategies, so as to provide a foundation for clinicians to develop more individualized and precise regimens and finally improve patients' prognosis. .
免疫疗法显著改善了非小细胞肺癌（NSCLC）的临床疗效，然而，随着免疫疗法的普及，免疫抵抗已成为一个不可避免的问题。免疫疗法可在肿瘤微环境中诱导广泛的细胞和分子改变。鉴于免疫抵抗机制尚未完全明确，且标准化化疗方案的疗效有限，迫切需要基于抵抗机制制定更有效的应对策略。在本综述中，我们旨在总结已知的免疫抵抗机制和可行策略，为临床医生制定更个体化、精准的治疗方案并最终改善患者预后提供依据。
